NASDAQ · Biotechnology

Actuate Therapeutics, Inc. (ACTU) Stock

$0.61 -10.13% NASDAQ: ACTU Healthcare

Valuation

MetricValue
Price$0.61
Market Cap$14.60M
P/E Ratio-0.92
P/B Ratio19.77
P/S Ratio0.00
EPS (TTM)$-1.06
52-Week High$8.49
52-Week Low$0.60
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-346.18%
ROA-393.39%
ROCE-275.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.41
Current Ratio2.33

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$0$0
Operating Profit$-20.0M$-25.0M$-25.0M$-22.0M
Net Profit$-20.0M$-25.0M$-27.0M$-22.0M
EPS$-1.34$-1.65$-3.26$-1.06
Op Margin————

Balance Sheet (USD)

Metric2022202320242025
Total Assets$20.0M$3.0M$9.0M$14.0M
Total Liabilities$6.0M$103.0M$9.0M$6.0M
Cash$20.0M$3.0M$9.0M$13.0M
Borrowings$0$0$0$0

Latest News

Actuate Therapeutics Says Elraglusib to be Evaluated in Phase 1/2 Trial to Find Treatments for Pediatric Neuroblastoma MT Newswires · Jun 9, 2026 Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma GlobeNewswire · Jun 9, 2026 Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer GlobeNewswire · Jun 1, 2026 Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program GlobeNewswire · May 11, 2026 Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors GlobeNewswire · May 6, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-18.0M$-22.0M$-22.0M$-19.0M
Investing Cash Flow$0$0$0$0
Financing Cash Flow$0$0$-2.0M$0
Net Cash Flow$1.0M$-17.0M$6.0M$5.0M
Free Cash Flow$-18.0M$-22.0M$-22.0M$-19.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.76
FCF Yield-101.23%
Quick Ratio1.25
Interest Coverage-1025.81
Return 1Y-71.86%
Return 3Y—
Return 5Y—

Ownership

Insiders Held14.84%
Institutions Held58.20%
Institutions Float Held68.34%
Institutional HolderSharesReport Date
Bios Capital Management, LP 10,049,9962026-03-31
Voss Capital, LP1,725,0002026-03-31
Blackrock Inc.427,1532026-03-31
Vanguard Capital Management LLC400,5292026-03-31
Geode Capital Management, LLC228,3312026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALECAlector, Inc. $2.08 +2.97% -1.84 $230.93M 0.00%
APLTApplied Therapeutics, Inc. $0.10 +0.00% -0.24 $14.86M 0.00%
ELTXElicio Therapeutics, Inc. $1.89 +4.42% -0.89 $36.04M 0.00%
MCRBSeres Therapeutics, Inc. $2.71 +3.04% -1.21 $26.24M 0.00%
MOLNMolecular Partners AG $3.91 -2.25% -2.08 $146.67M 0.00%

About Actuate Therapeutics, Inc.

Actuate Therapeutics, Inc. is led by CEO Daniel Schmitt, employs 10 people, headquartered in US, publicly traded since 2024.

Actuate Therapeutics, Inc. (ACTU) stock trades at $0.61 with a market capitalization of $14.60M. The stock is valued at a price-to-earnings (P/E) ratio of -0.92, price-to-book of 19.77, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.60 and $8.49, and currently trades 92.8% below its 52-week high.

On profitability, Actuate Therapeutics, Inc. generates a return on equity (ROE) of -346.18%, return on capital employed of -275.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides